Ovarian Cancer Trial, Recruiting NCT05444270 Sponsor: Yonsei University Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT05444270
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with epithelial ovarian cancer confirmed by a pathology test
  • People who have already completed standard first-line treatment for their ovarian cancer, which for advanced cases includes surgery to remove as much of the tumour as possible, followed by platinum-based chemotherapy
  • People who have 10 or fewer areas of cancer spread (metastases) in the body, where nearby lesions may be counted as one if they can be treated together in a single radiation plan
  • People whose individual areas of cancer spread are each no larger than 5 cm across
  • People aged 19 years or older
  • People whose blood test results within the past 60 days show adequate bone marrow function — specifically, enough white blood cells (neutrophils), platelets, and haemoglobin (note: blood transfusions to maintain haemoglobin levels are permitted)
  • People who are able to carry out basic daily activities with minimal or no assistance, as measured by a standard performance scale, within the past 60 days (confirm with trial site)
  • People who are willing to provide written consent to participate in the study before it begins

Who may not be able to join:

  • People whose cancer has spread to the brain
  • People with widespread cancer spread throughout the lining of the abdominal cavity (diffuse peritoneal carcinomatosis)
  • People who have a confirmed malignant fluid build-up around the lungs (malignant pleural effusion)
  • People who have previously received radiation therapy to any areas of cancer spread
  • People whose areas of cancer spread do not have clearly defined boundaries, making precise radiation targeting difficult
  • People who have had another invasive cancer in the past, unless they have been free of that cancer for more than 3 years — thyroid cancer, early-stage cervical cancer (CIS), basal cell skin cancer, and early gastric cancer are exceptions to this rule
  • People who are pregnant
  • People with serious heart conditions, including unstable chest pain or heart failure requiring hospitalisation in the past 6 months, or a significant heart attack in the past 6 months
  • People who have an active serious bacterial or fungal infection requiring intravenous antibiotics at the time of enrolment
  • People who have a flare-up of a chronic lung condition or other breathing problem that requires hospitalisation or would make it difficult to complete the treatment, at the time of enrolment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 82-2-2228-8095

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
26 October 2022
Est. completion
1 December 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

overall survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov